Insider Trading January 29, 2026

Saba Capital Reduces ECAT Stake with $2.95M Sale Over Two Days

Investor disposes 189,880 shares of BlackRock ESG Capital Allocation Term Trust across January 27-28, 2026; fund still shows strong yield and a 'GREAT' financial health rating

By Leila Farooq ECAT
Saba Capital Reduces ECAT Stake with $2.95M Sale Over Two Days
ECAT

Saba Capital Management, L.P., a roughly ten-percent holder of BlackRock ESG Capital Allocation Term Trust (NASDAQ: ECAT), sold 189,880 shares of common stock in two transactions on January 27 and January 28, 2026, for a combined $2.95 million. The trades priced between $15.53 and $15.54 per share. After the sales, Saba’s position decreased to 25,470,310 shares. ECAT, with a market capitalization of $1.54 billion, trades at $15.46 and carries a 21.45% dividend yield, while delivering a 16.5% total return over the past 12 months and holding a

Key Points

  • Saba Capital sold 189,880 ECAT shares on Jan 27-28, 2026, raising $2.95M.
  • After the two trades Saba’s holdings fell to 25,470,310 shares; sales were at $15.54 and $15.53 per share.
  • ECAT trades at $15.46, has a $1.54B market cap, 21.45% dividend yield, 16.5% one-year total return, and a "GREAT" financial health rating with low volatility per InvestingPro.

Saba Capital Management, L.P. - identified in filings as holding approximately ten percent of BlackRock ESG Capital Allocation Term Trust (NASDAQ: ECAT) - reduced its stake through two block sales on January 27 and January 28, 2026.

The combined disposition totaled 189,880 common shares and generated proceeds of $2.95 million. Executed across two transactions, the shares were sold at prices ranging from $15.53 to $15.54 per share.

Transaction details recorded in the filings show that on January 27 Saba Capital sold 83,984 shares at $15.54 per share. That sale brought its holdings down to 25,576,206 shares. The next day, January 28, Saba sold a further 105,896 shares at $15.53 each, leaving the firm with a reported 25,470,310 shares of ECAT.

Market context provided in the data notes that ECAT has a market capitalization of $1.54 billion and is trading at $15.46. The fund is reported to offer a 21.45% dividend yield, according to InvestingPro data. Over the last year ECAT has produced a 16.5% total return. InvestingPro also assigns the trust an overall financial health rating of "GREAT," and notes that the security typically experiences low price volatility.

While the filings document the precise volumes, prices, and resulting holdings following the two-day selling activity, they do not specify any motives for the transactions. The available public information focuses on the mechanics of the trades and the standing valuation and performance metrics for ECAT.


Clear summary

Saba Capital, a roughly ten-percent owner of BlackRock ESG Capital Allocation Term Trust (ECAT), executed two sales totaling 189,880 shares on January 27-28, 2026, for $2.95 million at prices between $15.53 and $15.54. After the trades, its stake stood at 25,470,310 shares. ECAT carries a 21.45% dividend yield, trades at $15.46, has a $1.54 billion market cap, returned 16.5% over the past year, and holds a "GREAT" financial health rating with generally low price volatility, per InvestingPro.

Key points

  • Saba Capital sold a total of 189,880 ECAT shares across two transactions on January 27 and January 28, 2026, for a combined $2.95 million.
  • Following the sales, the firm reported holdings of 25,470,310 shares; individual trades were 83,984 shares at $15.54 and 105,896 shares at $15.53.
  • ECAT is quoted at $15.46, has a $1.54 billion market capitalization, offers a reported 21.45% dividend yield, and produced a 16.5% total return over the prior year while carrying a "GREAT" financial health rating and low price volatility per InvestingPro.

Risks and uncertainties

  • Motives for Saba Capital’s sales are not disclosed in the filings; the public record documents quantities, prices, and resulting holdings but does not explain intent.
  • Although InvestingPro reports that ECAT generally trades with low price volatility, future price movements are not detailed in the available information.
  • The data relies on InvestingPro figures for yield, total return, and the financial health rating; those metrics represent the sources cited in the filings rather than additional verification.

This report is limited to the facts contained within the transaction filings and the published InvestingPro metrics; no additional claims or interpretations beyond those data points are offered here.

Risks

  • The filings do not disclose the motivation behind Saba Capital’s sales, leaving intent unclear.
  • Future price movements are not detailed; despite low volatility noted by InvestingPro, market behavior can change.
  • Reported yield, performance, and health ratings are those provided by InvestingPro and are subject to the limitations of those metrics.

More from Insider Trading

Elutia director buys $20,800 in Class A shares as company reports revenue gain and Nasdaq notice Feb 2, 2026 Symbotic Accounting Chief Disposes $457,722 in Shares as Company Prices 10M-Share Offering; Goldman Lowers Rating Feb 2, 2026 Wintrust Financial EVP Sells 5,000 Shares as Firm Announces Dividend Hike and Multiple Price-Target Upgrades Jan 30, 2026 Cantor Fitzgerald Affiliates Dispose of Satellogic Shares in $2.94M Transaction Block Jan 30, 2026 Navan Interim CFO Executes $37,044 Sell-to-Cover Transaction Jan 30, 2026